Dr. Clarissa Desjardins founded and was the CEO of Clementia, a Montreal-based company focused on developing therapies for rare pediatric bone diseases. Clementia has offices in Montreal and Boston and was Nasdaq-listed company until its acquisition by Ipsen in early 2019 for $1.3 billion dollars. Continuing to operate in Montreal, Clementia is advancing a Phase 3 trial in fibrodysplasia ossificans progressiva (FOP) and a phase 2 trial in multiple osteochondroma. The company is also preparing to submit a New Drug Application (NDA) for FOP to the FDA in 2021. Dr. Desjardins is an award-winning entrepreneur with more than 25 years of biotechnology experience. She has founded three successful biotech companies, leading all aspects of company creation including conception and financing. She founded Advanced Bioconcept, a research reagent and diagnostics company sold to NEN Life Sciences (Perkin Elmer) in 1998. Dr. Desjardins also co-founded Caprion Pharmaceuticals, a biotechnology company focused on proteomic biomarker discovery and drug development, where she was Executive Vice-President of corporate development. Prior to Clementia, Clarissa was CEO at the Centre d’excellence en médecine personnalisée (CEPMED), a Montreal-based non-profit organization created to promote personalized medicine. Dr. Desjardins is the recipient of the 2018 Bloom Burton Award for her contribution to Canada’s innovative healthcare industry, the BRIO award for outstanding contributions to the biotechnology industry from the Quebec Biotechnology Association and was named one of 2017’s Fiercest Women in Life Sciences by FiercePharma. Dr. Desjardins currently sits on the board of BELLUS Health, INSMED and Xenon. Dr. Desjardins earned a doctorate in neurology and neurosurgery from McGill University’s Faculty of Medicine.